"We believe that MultiStem has the potential to improve standard of care for patients that have suffered a stroke while also extending the treatment window, providing a potential treatment option for many more patients," said Athersys interim CEO William Lehmann, Jr. "We look forward to the topline results which Healios is targeting for release later this year."
Shares of Athersys were up nearly 6% in midday trading.
Price: 1.63, Change: +0.10, Percent Change: +6.21
|Barclays Downgrades Cardinal Health to Equalweight F...|
|European Bourses Track Higher Midday on Federal Rese...|
|Barclays Upgrades AmerisourceBergen to Overweight Fr...|
|Broadcom Agrees to Buy VMware in $61 Billion Deal|
|US Dollar Lower Early Thursday Ahead of GDP, Jobless...|